Skip to main content
Clinical Trials/NL-OMON27777
NL-OMON27777
Not yet recruiting
Not Applicable

Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High- risk Relapsed or Refractory CLLA prospective multi-centre phase II study

Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl0 sites50 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Refractory or relapsed Chronic Lymphocytic Leukemia
Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl
Enrollment
50
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl

Eligibility Criteria

Inclusion Criteria

  • 1\. B\-CLL confirmed according to WHO Classification;
  • 2\. Fludarabine refractory, defined as no response or relapse within 12 months after the last administration of fludarabine monotherapy or fludarabine containing regimen, and needing treatment, or Refractory or relapsed and needing treatment and having deletion of 17p13 or Refractory or relapsed within 24 months after the last administration of fludarabine combined with a monoclonal antibody and needing treatment;

Exclusion Criteria

  • 1\. Intolerance to exogenous protein administration;
  • 2\. Previously treated with DHAP;

Outcomes

Primary Outcomes

Not specified

Similar Trials